+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Farber's Disease Global Market Report 2025

  • PDF Icon

    Report

  • 175 Pages
  • July 2025
  • Region: Global
  • The Business Research Company
  • ID: 6105052
The farber's disease market size has grown strongly in recent years. It will grow from $1.87 billion in 2024 to $1.98 billion in 2025 at a compound annual growth rate (CAGR) of 6%. The growth during the historic period can be credited to increasing awareness and diagnosis rates, greater adoption of genetic testing, a rise in research efforts focused on lysosomal storage disorders, the expansion of rare disease registries, and growing support from patient advocacy organizations.

The farber's disease market size is expected to see strong growth in the next few years. It will grow to $2.48 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to the expanding pipeline of targeted therapies, increasing government incentives and orphan drug designations, broader access to specialized healthcare services, rising investments in rare disease-focused biotech startups, and the growing use of next-generation sequencing. Key trends expected during this period include progress in gene therapy technologies, the integration of artificial intelligence for diagnosing rare diseases, technology-enabled biomarker discovery, advancements in enzyme replacement therapies, and improvements in newborn screening programs.

The increasing prevalence of rare genetic disorders is anticipated to drive the growth of the Farber’s disease market in the coming years. Rare genetic disorders are inherited conditions caused by mutations in an individual’s DNA, affecting a very small portion of the population. This rise in prevalence is largely attributed to advancements in diagnostic technologies that allow for earlier and more accurate detection of conditions that were previously undiagnosed or misdiagnosed. Farber’s disease plays a significant role in addressing the rise in rare genetic disorders by acting as a model for the development of targeted therapies and supporting research in enzyme replacement treatments for ultra-rare conditions. For example, in November 2022, the Australian Government Department of Health and Aged Care reported that rare diseases - defined as affecting fewer than 5 in 10,000 people - impact around 2 million individuals, or 8% of the population, with over 7,000 known chronic or life-threatening conditions. Hence, the rising prevalence of rare genetic diseases is contributing to the expansion of the Farber’s disease market.

The rising investment in clinical trials is expected to drive the growth of the Farber’s disease market in the coming years. Clinical trials are research studies conducted in humans to assess the safety, effectiveness, and outcomes of medical interventions, including drugs, treatments, or medical devices. This growing investment is fueled by the increasing demand for innovative therapies, spurred by advancements in medical science, personalized medicine, and the pressing need to address unmet healthcare challenges. Farber’s disease underscores the importance of such investments by emphasizing the need for research focused on rare and underserved genetic disorders. For example, in October 2024, Citeline, a US-based provider of pharmaceutical intelligence solutions, reported that TrialTrove recorded 9,959 Phase I-III clinical trials set to begin in 2024 involving at least one drug - a 9.4% rise compared to 2023. Thus, the growing investment in clinical trials is contributing to the expansion of the Farber’s disease market.

In September 2022, Idera Pharmaceuticals, a biotechnology company based in the US, acquired Aceragen for an undisclosed sum. This acquisition was intended to strengthen Idera Pharmaceuticals’ position in the rare disease market by adding Aceragen’s pipeline to its portfolio, including ACG-801, a therapy in development for Farber’s disease. The move aims to address a significant unmet medical need and accelerate the advancement of enzyme replacement therapies. Aceragen Inc., also a US-based biopharmaceutical company, is actively developing ACG-801, an enzyme replacement therapy designed specifically to treat Farber disease, a rare lysosomal storage disorder.

Major players in the farber's disease market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Mount Sinai Health System, Emory Healthcare, Kyowa Kirin Co. Ltd., BioMarin Pharmaceutical Inc., Children’s National Hospital, Medanta - The Medicity (Global Health Ltd.), Amicus Therapeutics Inc., JCR Pharmaceuticals Co. Ltd., Spark Therapeutics Inc., REGENXBIO Inc., Passage Bio Inc., Protalix BioTherapeutics Inc., Medicover Hospitals, Minoryx Therapeutics S.L., bluebird bio Inc., and Avrobio Inc.

North America was the largest region in the farber's disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in farber's disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the farber's disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Farber's disease is a rare inherited disorder resulting from a deficiency of the enzyme acid ceramidase, which causes fatty substances to build up in body tissues. It is passed down through an autosomal recessive pattern and usually appears during infancy. Common symptoms include joint deformities, subcutaneous nodules, and a gradual decline in neurological function. The disease progresses over time and can be life-threatening, necessitating coordinated care and symptom-focused treatment.

Farber's disease primarily exists in two forms: classical and non-classical. The classical form is the most common type and is marked by early-onset symptoms such as joint abnormalities, subcutaneous nodules, and progressive neurological deterioration. Available treatments include enzyme replacement therapy, gene therapy, symptomatic management, bone marrow transplantation, and supportive interventions for symptoms like joint issues, hearing loss, respiratory problems, and skin-related conditions. Key end-users include hospitals, specialized clinics, diagnostic facilities, and others.

The farber's disease market research report is one of a series of new reports that provides farber's disease market statistics, including the farber's disease industry global market size, regional shares, competitors with the farber's disease market share, detailed farber's disease market segments, market trends, and opportunities, and any further data you may need to thrive in the farber's disease industry. This farber's disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The farber's disease market includes revenues earned by rehabilitation services, nutritional support services, and clinical trial access services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Farber's Disease Market Characteristics3. Farber's Disease Market Trends And Strategies4. Farber's Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Farber's Disease Growth Analysis And Strategic Analysis Framework
5.1. Global Farber's Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Farber's Disease Market Growth Rate Analysis
5.4. Global Farber's Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Farber's Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Farber's Disease Total Addressable Market (TAM)
6. Farber's Disease Market Segmentation
6.1. Global Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Classical Farber's Disease
  • Non-Classical Farber's Disease
6.2. Global Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Enzyme Replacement Therapy
  • Symptomatic Treatment
  • Gene Therapy
  • Bone Marrow Transplant
  • Supportive Care
6.3. Global Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Joint Involvement And Deformities
  • Hearing Loss
  • Respiratory Distress
  • Dermatological Manifestations
6.4. Global Farber's Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Other End-Users
6.5. Global Farber's Disease Market, Sub-Segmentation Of Classical Farber's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Type 1 Severe Infantile Form
  • Type 2 Intermediate Childhood Form
  • Type 3 Juvenile-Onset Form
6.6. Global Farber's Disease Market, Sub-Segmentation Of Non-Classical Farber's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Type 4 Neurological Predominant Form
  • Type 5 Visceral Predominant Form
  • Type 6 Cardiopulmonary Involvement Form
7. Farber's Disease Market Regional And Country Analysis
7.1. Global Farber's Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Farber's Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Farber's Disease Market
8.1. Asia-Pacific Farber's Disease Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Farber's Disease Market
9.1. China Farber's Disease Market Overview
9.2. China Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Farber's Disease Market
10.1. India Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Farber's Disease Market
11.1. Japan Farber's Disease Market Overview
11.2. Japan Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Farber's Disease Market
12.1. Australia Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Farber's Disease Market
13.1. Indonesia Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Farber's Disease Market
14.1. South Korea Farber's Disease Market Overview
14.2. South Korea Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Farber's Disease Market
15.1. Western Europe Farber's Disease Market Overview
15.2. Western Europe Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Farber's Disease Market
16.1. UK Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Farber's Disease Market
17.1. Germany Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Farber's Disease Market
18.1. France Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Farber's Disease Market
19.1. Italy Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Farber's Disease Market
20.1. Spain Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Farber's Disease Market
21.1. Eastern Europe Farber's Disease Market Overview
21.2. Eastern Europe Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Farber's Disease Market
22.1. Russia Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Farber's Disease Market
23.1. North America Farber's Disease Market Overview
23.2. North America Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Farber's Disease Market
24.1. USA Farber's Disease Market Overview
24.2. USA Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Farber's Disease Market
25.1. Canada Farber's Disease Market Overview
25.2. Canada Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Farber's Disease Market
26.1. South America Farber's Disease Market Overview
26.2. South America Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Farber's Disease Market
27.1. Brazil Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Farber's Disease Market
28.1. Middle East Farber's Disease Market Overview
28.2. Middle East Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Farber's Disease Market
29.1. Africa Farber's Disease Market Overview
29.2. Africa Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Farber's Disease Market Competitive Landscape And Company Profiles
30.1. Farber's Disease Market Competitive Landscape
30.2. Farber's Disease Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Mount Sinai Health System Overview, Products and Services, Strategy and Financial Analysis
31. Farber's Disease Market Other Major And Innovative Companies
31.1. Emory Healthcare
31.2. Kyowa Kirin Co. Ltd.
31.3. BioMarin Pharmaceutical Inc.
31.4. Children’s National Hospital
31.5. Medanta - The Medicity (Global Health Ltd.)
31.6. Amicus Therapeutics Inc.
31.7. JCR Pharmaceuticals Co. Ltd.
31.8. Spark Therapeutics Inc.
31.9. REGENXBIO Inc.
31.10. Passage Bio Inc.
31.11. Protalix BioTherapeutics Inc.
31.12. Medicover Hospitals
31.13. Minoryx Therapeutics S.L.
31.14. bluebird bio Inc.
31.15. Avrobio Inc.
32. Global Farber's Disease Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Farber's Disease Market34. Recent Developments In The Farber's Disease Market
35. Farber's Disease Market High Potential Countries, Segments and Strategies
35.1 Farber's Disease Market In 2029 - Countries Offering Most New Opportunities
35.2 Farber's Disease Market In 2029 - Segments Offering Most New Opportunities
35.3 Farber's Disease Market In 2029 - Growth Strategies
35.3.1 Market Trend Based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright And Disclaimer

Executive Summary

Farber's Disease Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on farber's disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase:

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for farber's disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The farber's disease market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Type Of Farber's Disease: Classical Farber's Disease; Non-Classical Farber's Disease
2) By Treatment: Enzyme Replacement Therapy; Symptomatic Treatment; Gene Therapy; Bone Marrow Transplant; Supportive Care
3) By Clinical Symptoms: Joint Involvement And Deformities; Hearing Loss; Respiratory Distress; Dermatological Manifestations
4 By End-User: Hospitals; Specialty Clinics; Diagnostic Centers; Other End-Users

Subsegments:

1) By Classical Farber's Disease: Type 1 Severe Infantile Form; Type 2 Intermediate Childhood Form; Type 3 Juvenile-Onset Form
2) By Non-Classical Farber's Disease: Type 4 Neurological Predominant Form; Type 5 Visceral Predominant Form; Type 6 Cardiopulmonary Involvement Form

Key Companies Profiled: Pfizer Inc.; Merck & Co. Inc.; Sanofi S.A.; Takeda Pharmaceutical Company Limited; Mount Sinai Health System

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery Format: PDF, Word and Excel Data Dashboard.

Companies Mentioned

  • Pfizer Inc.
  • Merck & Co. Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Mount Sinai Health System
  • Emory Healthcare
  • Kyowa Kirin Co. Ltd.
  • BioMarin Pharmaceutical Inc.
  • Children’s National Hospital
  • Medanta - The Medicity (Global Health Ltd.)
  • Amicus Therapeutics Inc.
  • JCR Pharmaceuticals Co. Ltd.
  • Spark Therapeutics Inc.
  • REGENXBIO Inc.
  • Passage Bio Inc.
  • Protalix BioTherapeutics Inc.
  • Medicover Hospitals
  • Minoryx Therapeutics S.L.
  • bluebird bio Inc.
  • Avrobio Inc.